Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma By Ogkologos - July 2, 2026 53 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-3 study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Do Cancer Survivors Have To Be Positive All the Time? Letting... November 10, 2021 The Childhood Cancer Data Initiative: Transforming the Pediatric Cancer Landscape through... August 15, 2019 Researchers Find New, Effective Tools to Determine Breast Cancer Risk Using... December 29, 2020 FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer January 7, 2026 Load more HOT NEWS ESMO Call for Cancer Care Safeguards Reflected in the EU’s Health... Male Patients with Cancer at Higher Risk of Severe Disease Course... The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce Teen With Cancer On Dream Trip To NASA Gets Surprise Call...
